Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of NKX019 in B-cell Malignancies
NCT05020678Phase 1Active, not recruiting
- Sponsor
- Nkarta
- Start
- Aug 2021
- Primary completion
- Mar 2025
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of NKX019 in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL), sponsored by Nkarta. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 30 days, Proportion of subjects experiencing dose-limiting toxicities at 28 days and 1 more. Started Aug 2021; status: active, not recruiting.
02
Drugs
NKX019
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05020678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05020678.